Bioneer Corporation (064550) - Total Liabilities

Latest as of September 2025: ₩147.32 Billion KRW ≈ $99.83 Million USD

Based on the latest financial reports, Bioneer Corporation (064550) has total liabilities worth ₩147.32 Billion KRW (≈ $99.83 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Bioneer Corporation long-term investment intensity to see how much of total assets are deployed in long-term investments.

Bioneer Corporation - Total Liabilities Trend (2011–2024)

This chart illustrates how Bioneer Corporation's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Bioneer Corporation assets under control.

Bioneer Corporation Competitors by Total Liabilities

The table below lists competitors of Bioneer Corporation ranked by their total liabilities.

Company Country Total Liabilities
T.K.S. Technologies Public Company Limited
BK:TKS
Thailand ฿1.04 Billion
Aqualis ASA
OL:AQUA
Norway Nkr101.77 Million
KB Star REIT Co. Ltd.
KO:432320
Korea ₩935.70 Billion
Cornish Metals Inc.
V:CUSN
Canada CA$15.90 Million
Singatron Enterprise Co Ltd
TWO:6126
Taiwan NT$4.20 Billion
Bharat Wire Ropes Limited
NSE:BHARATWIRE
India Rs1.79 Billion
Readytech Holdings Ltd
AU:RDY
Australia AU$120.72 Million
Mirae Corporation
KO:025560
Korea ₩52.99 Billion

Liability Composition Analysis (2011–2024)

This chart breaks down Bioneer Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 064550 net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.18 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.69 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.39 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Bioneer Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Bioneer Corporation (2011–2024)

The table below shows the annual total liabilities of Bioneer Corporation from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 ₩105.29 Billion
≈ $71.36 Million
+30.62%
2023-12-31 ₩80.61 Billion
≈ $54.63 Million
+28.49%
2022-12-31 ₩62.74 Billion
≈ $42.51 Million
+5.67%
2021-12-31 ₩59.37 Billion
≈ $40.23 Million
+30.31%
2020-12-31 ₩45.56 Billion
≈ $30.88 Million
-11.52%
2019-12-31 ₩51.49 Billion
≈ $34.89 Million
+61.83%
2018-12-31 ₩31.82 Billion
≈ $21.56 Million
+0.85%
2017-12-31 ₩31.55 Billion
≈ $21.38 Million
-16.08%
2016-12-31 ₩37.59 Billion
≈ $25.48 Million
+0.38%
2015-12-31 ₩37.45 Billion
≈ $25.38 Million
+0.80%
2014-12-31 ₩37.16 Billion
≈ $25.18 Million
-8.02%
2013-12-31 ₩40.40 Billion
≈ $27.38 Million
+10.05%
2012-12-31 ₩36.71 Billion
≈ $24.88 Million
+11.94%
2011-12-31 ₩32.79 Billion
≈ $22.22 Million
--

About Bioneer Corporation

KQ:064550 Korea Biotechnology & Medical Research
Market Cap
$122.50 Million
₩180.76 Billion KRW
Market Cap Rank
#18478 Global
#834 in Korea
Share Price
₩8180.00
Change (1 day)
-0.97%
52-Week Range
₩5790.00 - ₩15500.00
All Time High
₩93200.00
About

Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analys… Read more